Abstract
Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality. While there are a number of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential. The completion of the Plasmodium falciparum genome and a growing understanding of parasite biology are fueling the search for novel drug targets. Despite this, few targets have been chemically validated in vivo. The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets. This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery. Several chemical scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the malarial enzyme over that from the human host. Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been observed for a number of the identified series. Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease. These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy. The challenge remains to identify compounds with the necessary combination of potency and metabolic stability to allow identification of a clinical candidate.
Keywords: Malaria, Plasmodium, pyrimidine biosynthesis, dihydroorotate dehydrogenase, drug discovery
Infectious Disorders - Drug Targets
Title: Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy
Volume: 10 Issue: 3
Author(s): Margaret A. Phillips and Pradipsinh K. Rathod
Affiliation:
Keywords: Malaria, Plasmodium, pyrimidine biosynthesis, dihydroorotate dehydrogenase, drug discovery
Abstract: Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality. While there are a number of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential. The completion of the Plasmodium falciparum genome and a growing understanding of parasite biology are fueling the search for novel drug targets. Despite this, few targets have been chemically validated in vivo. The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets. This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery. Several chemical scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the malarial enzyme over that from the human host. Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been observed for a number of the identified series. Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease. These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy. The challenge remains to identify compounds with the necessary combination of potency and metabolic stability to allow identification of a clinical candidate.
Export Options
About this article
Cite this article as:
A. Phillips Margaret and K. Rathod Pradipsinh, Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy, Infectious Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187152610791163336
DOI https://dx.doi.org/10.2174/187152610791163336 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Genipin Inhibits the Induction of Inducible Nitric Oxide Synthase Through the Inhibition of NF-κB Activation in Rat Hepatocytes
Drug Metabolism Letters Small Molecule Immunosuppressive Agents in Experimental and Clinical Transplantation
Current Drug Targets - Cardiovascular & Hematological Disorders In Search of Pathogenic Mechanisms in Endometriosis: The Challenge for Molecular Cell Biology
Current Molecular Medicine Understanding Adverse Drug Reactions and Drug Allergies: Principles, Diagnosis and Treatment Aspects
Recent Patents on Inflammation & Allergy Drug Discovery A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease
Current Neuropharmacology Modulation of TNF Receptor Family Members to Inhibit Autoimmune Disease
Current Drug Targets - Inflammation & Allergy Small Intestinal Injury Caused by NSAIDs/Aspirin: Finding New from Old
Current Medicinal Chemistry Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design The Immunological Function of iGb3
Current Protein & Peptide Science Current Key Points in Management for Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Pharmacogenomics in the Americas: The Impact of Genetic Admixture
Current Drug Targets Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology Conformational Analysis Corresponding to Intra-Chain Disulfide Bridged Peptides in Proteins of Known Three-Dimensional Structure
Protein & Peptide Letters Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery Mesangial Cells and Glomerular Inflammation: From the Pathogenesis to Novel Therapeutic Approaches
Current Drug Targets - Inflammation & Allergy Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued)